$ALNY

Ionis (IONS) and AstraZeneca (AZN) presented full data from a failed trial of Wainua for transthyretin amyloid cardiomyopathy (ATTR-CM). Jefferies sees neutral to negative implications for Alnylam (ALNY), which is developing similar drugs. ALNY shares closed flat, IONS down 2%, and AZN down 1% on Friday. The trial missed its primary goal, raising doubts about ALNY's TTR business.

Alnylam Pharmaceuticals' stock fell 4.9% pre-market as negative data from a competitor's trial raised concerns about its RNA-silencing drug class. Wells Fargo cut its price target to $256. The company also faces competitive pressure and lowered its 2026 revenue guidance in July.

Alnylam Pharmaceuticals (ALNY) shares dropped 6% after AstraZeneca's Phase 3 trial for a silencer drug targeting ATTR-CM failed, showing no improvement in patients already on stabilizer drugs. The results raise concerns about silencer drugs in the competitive ATTR-CM treatment market, which is expected to be worth billions.

AstraZeneca's Phase 3 trial for a heart disease drug (a silencer) failed, showing no benefit for patients already on stabilizers. The study involved ATTR-CM patients and was conducted with Ionis Pharmaceuticals. The results may impact other companies like Alnylam and BridgeBio, which also market ATTR-CM drugs.

Moderna is raising $2 billion in convertible debt following the success of its personalized cancer vaccine developed with Merck. The vaccine uses an algorithm to analyze tumor mutations and create a bespoke mRNA treatment. Some investors question the necessity of personalization. Meanwhile, a U.S. biotech crackdown on China could benefit European companies, and a rival drug failure may impact Alnylam's ATTR-CM franchise.

A post hoc analysis of the HELIOS-B trial found that vutrisiran, developed by Alnylam Pharmaceuticals, stabilized right ventricular function in patients with ATTR-CM, reducing mortality and cardiovascular risks. The study, published in JAMA Cardiology, showed significant improvements in RVFWS and RVFWS/PASP compared to placebo. Funding and disclosures were reported by Alnylam and other healthcare companies.

The ATTR-CM market is changing in 2026 due to new treatments and regulatory shifts. Pfizer's tafamidis faces competition from BridgeBio's Attruby and Alnylam's Amvuttra. Regulatory scrutiny of PBMs may impact access to newer therapies, with patient advocacy groups and economists monitoring the situation. Industry analysts suggest competition could lower costs and improve outcomes, depending on PBM transparency reforms.

Moderna (MRNA) shares fell 7.7% premarket after a 177% surge following positive trial results for its mRNA cancer vaccine. Five biotech stocks with imminent FDA catalysts are highlighted: Regeneron (REGN), Ultragenyx (RARE), Alnylam (ALNY), Merck (MRK), and Ionis (IONS). Each has recent approvals, upcoming data presentations, or earnings events that could impact their stock prices. Financial metrics and analyst targets are provided for each company. Bitcoin hit $72k after Trump's crypto legislat

BMO Capital initiated coverage on Alnylam Pharmaceuticals (ALNY) with an Outperform rating and $318 price target, BioMarin Pharmaceutical (BMRN) with an Outperform rating and $98 target, and Ionis Pharmaceuticals (IONS) with a Market Perform rating and $60 target. Cantor Fitzgerald initiated Agomab Therapeutics (AGMB) with an Overweight rating. CLSA initiated KE Holdings (BEKE) with an Outperform rating and $23.8 target.

Alnylam Pharmaceuticals (ALNY) cut its full-year 2026 TTR product sales guidance by about $200 million, citing normalized growth, and is also facing a securities law investigation. The stock fell 19.25% over 30 days and 43.24% year to date. Simply Wall St’s “undervalued” narrative sets a fair value of $434.72 versus $227.12 last close.